Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Is Ocugen Stock Headed for a Rally?

Stock MarketsSep 06, 2021 04:00PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Is Ocugen Stock Headed for a Rally?

Various companies have been engaged in producing COVID-19 vaccines since the onset of the pandemic.

Clinical-stage biotech firm Ocugen (NASDAQ:OCGN) joined the race in December 2020, announcing its partnership with India-based Bharat Biotech. Ocugen collaborated with the Indian biotech company to jointly develop Covaxin. 

The announcement helped its stock to propel from under 30 cents a share to a stunning, eventual high of $18.77 a share in February. However, prices plummeted to nearly $9 per share in the next month.

As rival companies came forward with their vaccines while Ocugen lagged behind, the stock started to bleed. (See OCGN stock charts on TipRanks)

However, OCGN stock is once again witnessing an upward move. Here’s a detailed analysis to find out what’s really happening with the stock. I'm neutral on Ocugen.

Delta Variant Concerns Pushing OCGN Stock up

Newly discovered variants of COVID-19 have been a major cause of concern lately. These variants are more infectious, and resistant, to the already existing COVID-19 vaccines. The Delta variant is one such dangerous strain that has caught the attention of people worldwide.

This new variant has piqued global interest in Ocugen, and its Covaxin. Notably, Covaxin is yet to receive approval from FDA. However, the once-forgotten OCGN stock is again back in the discussion, with stock prices moving up by a decent 8.5% in August. 

According to many analysts, value investors aren’t interested in this stock. Rather, it is mainly retail investors who are eyeing Ocugen for some quick profit.

Short-term Catalyst behind the Sudden Spike

Ocugen has been jointly developing Covaxin with Bharat Biotech for use in the North American market. Share prices suffered a decline when Ocugen was denied emergency-use authorization from the FDA, which recommended that the company apply for a biologics-license application instead.

Health Canada is reviewing Covaxin currently. It has not yet been granted approval. However, the news of review was enough to push Ocugen stock higher. 

Moreover, the company intends to submit an Investigational New Drug application for one of its gene therapy candidates. OCU400 is designed to target retinal diseases. Ocugen has already started to assess options to begin trials in Europe in 2022.

Ocugen Needs to Progress

The biotech company released a much-awaited business update on August 6. Ocugen failed to generate revenue during the second quarter. Unlike many of its rivals, it doesn’t have any commercialized products at the moment. 

On top of that, it posted a net loss of $26 million during Q2. Expenses related to research and development stood at $18.9 million in the current quarter, as opposed to $1.6 million last year. In addition, administrative expenses increased by 279.8% year-over-year, to $6.8 million. 

As of June 30, cash and cash equivalents stood at $115.6 million.

Wall Street's Take

As per TipRanks' analyst rating consensus, Ocugen stock is a Moderate Buy. Out of four analysts, there are two Buy recommendations, and two Hold recommendations.

The average OCGN price target is $8.88. The analyst price targets range from a high of $15 per share, to a low of $4.50 per share. 

Bottom Line

Ocugen stock could very well profit from the mounting global concerns about the Delta variant.

There might even be a stock rally. However, the company is badly in need of positive regulatory updates right now.

It's an interesting play, but not without risk. 

Disclosure: At the time of publication, Chris MacDonald did not have a position in any of the securities mentioned in this article

Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.

Is Ocugen Stock Headed for a Rally?
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email